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Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar,
Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae,
genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in
humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified
as a Category A Priority pathogen and overlap select agent by CDC/USDA due to
its potential impact on public health and agriculture. There is a gap in the safety
and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine
TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn
vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this
review, problems of traditional vaccines and the safety and efficacy of recently reported
novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are
discussed.
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Rift Valley fever (RVF) is a mosquito-borne zoonotic disease
endemic to sub-Saharan Africa, and has spread into Egypt,
Madagascar, and the Arabian peninsula (Swanepoel and Coetzer,
2004). RVF is characterized by high rate of abortion or fetal
malformation in ruminants, and hemorrhagic fever, neurolog-
ical disorder, or blindness in humans (Ikegami and Makino,
2011). Rift Valley fever virus (RVFV: family Bunyaviridae, genus
Phlebovirus) has a tripartite negative-stranded RNA genome:
S-, M-, and L-segments. S-segment encodes the N and NSs
genes in an ambisense manner, M-segment encodes the Gn,
Gc, 78 kD and NSm genes, and L-segment encodes the L gene
(Ikegami, 2012). NSs and NSm are non-structural proteins,
and NSs is a major virulence factor of RVFV (Bouloy et al.,
2001). RVFV is classified as a Category A Priority Pathogen
by NIAID/NIH, and overlap select agent by US Department of
Health and Human Services (HHS) and Agriculture (USDA).
Only vaccination can effectively prevent the spread of RVFV,
and the development of live-attenuated, inactivated or other
available vaccines for RVF was reviewed previously (Ikegami
and Makino, 2009). Here, we review the development of
novel candidate vaccines for RVF in recent years such as sub-
unit vaccines, non-spreading RVFV replicons, alphavirus repli-
cons, adenovirus replicons, poxvirus vector, and Newcastle
virus vector.
TRADITIONAL STRATEGIES
There is a gap between safety and immunogenicity for RVF
vaccine development; (1) live-attenuated vaccines are immuno-
genic and induce protective immunity by a single dose
while lacking safety due to a potential of reversion to vir-
ulence or spread into environment, (2) formalin-inactivated
vaccines are safe in animals and humans, while lacking
immunogenicity to induce sufficient neutralizing antibody by a
single dose.
The live-attenuated MP-12 strain was developed by 12 serial
mutagenesis of wild-type (wt) ZH548 strain by 5-fluorouracil
(Caplen et al., 1985), and encodes virulent S-segment and atten-
uated M- and L-segments (Billecocq et al., 2008). MP-12 is safe
and immunogenic in ruminants and humans, and is excluded
from the select agent rule in the US. The attenuation of MP-
12 occurs by point mutations, which raises two concerns; (1) a
potential of reversion to virulence and (2) a lack of DIVA marker
(differentiating infected from vaccinated animals). In addition,
a past study suggested that MP-12 causes abortion and fetal
malformation in ewes when vaccinated at an early stage of preg-
nancy (Hunter et al., 2002). Thus, further improvement of MP-12
is warranted. Two segmented recombinant MP-12 (r2segMP12)
encoding Gn and Gc (nt.411 to 3614 of M-segment) in place of
NSs, and lacking M-segment was created and improved safety
by reducing the risk of potential reassortment with wt RVFV
(Brennan et al., 2011). Lihoradova et al. showed that a recom-
binant MP-12 lacking NSs is highly efficacious and useful for
DIVA in a mouse model (Lihoradova et al., 2012). The efficacy of
those improved MP-12 in ruminants and non-human primates
are yet to be determined. On the other hand, live-attenuated can-
didate vaccines derived from wt RVFV strains other than ZH548
have been developed for veterinary use. A natural plaque iso-
late from 74HB59 strain, named the Clone 13 strain, encodes a
69% in-frame truncation in the NSs gene (Muller et al., 1995),
and is completely attenuated in animals due to a lack of func-
tional NSs, regardless of the wt M- and L-segments (Bouloy
et al., 2001). Clone 13 was safe in ewes at 15, 50, and 100 days
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of pregnancy, while efficacious with at least 105 pfu per dose
(Dungu et al., 2010). Clone 13 induced neutralizing antibodies by
day 7 without developing viremia in cattle (von Teichman et al.,
2011). The recombinant ZH501 strain lacking both NSs and NSm
genes (NSs-NSm rRVFV vaccine) also safely induced protec-
tive immunity in ewes at 42 days of pregnancy (Bird et al., 2011).
Those vaccines encode a large deletion of RVFV gene(s), and are
useful for DIVA with a minimum concern of reversion to viru-
lence. However, those candidate vaccines are classified as select
agents in the US.
The formalin-inactivated Salk Institute-Government Services
Division (TSI-GSD)-200 vaccine was developed by using diploid
rhesus lung cell line (FRhL-2, DBS 103 cells) (Kark et al., 1982).
Among 598 vaccinees, TSI-GSD-200 vaccine elicited Plaque
Reduction Neutralizing Test: PRNT80 1:40 or more in 90.3% after
three doses (s.c.), while PRNT80 1:40 was maintained in 50% of
vaccines only for 287 days without subsequent boosters (Pittman
et al., 2000).
SUBUNIT VACCINES
Preparation of inactivated RVFV requires high containment facil-
ities. Also, use of chemicals such as formalin may modify RVFV
epitopes. Efficacy of highly purified Gn ectodomain was tested in
mice (de Boer et al., 2010). Gn ectodomain (Gn-e) lacking 109
aa. of Gn C-terminus was expressed with C-terminus His-tag in
Drosophila Schneider (S2) cells using an insect expression vector
encoding an inducible metallothionein promoter and Drosophila
BiP secretion signal. Mice vaccinated intraperitoneally twice with
Gn-e with Stimune (a water-in-oil adjuvant) induced neutral-
izing antibodies after the second dose and survived challenge
with RVFV M35/74 strain (South African strain) (Table 1). In a
later study, the Gn-e was fused with Flag-tag, enterokinase cleav-
age site and three Strep-tags, and purified from Drosophila S2
cells with Strep-Tactin Sepharose (Kortekaas et al., 2012). The
purified Gn-e was named GneS3, and formulated in Stimune
adjuvant. Lambs subcutaneously vaccinated once with GneS3
vaccine induced neutralizing antibodies in four out of six lambs
at 19 days post vaccination, and were protected from viramia and
fever after challenge with recombinant M35/74 strain (Table 1).
On the other hand,mild tomoderate swelling of the injection sites
were observed in vaccinated lambs. The purified Gn ectodomain
will be useful as human RVF vaccine because it is superior to the
TSI-GSD-200 vaccine in the large scale production without a risk
of infection.
NON-SPREADING RVFV REPLICONS
Recently, using reverse genetics, RVFV itself has been modified
into non-spreading replicon for vaccine use. Kortekaas et al. gen-
erated reverse genetics system for M35/74 strain and used it
for production of replicons which can infect mammalian cells
but cannot spread to neighboring cells (Kortekaas et al., 2011).
BHK cells infected with fowlpoxvirus encoding T7 RNA poly-
merase were transfected with plasmids encoding RVFV genome
S-GFP (NSs was replaced with GFP) and L as well as plas-
mid encoding M ORF. The resulting RVFV replicon particles
(RRPs) in the supernatants yielded up to 1 × 104.8 TCID50. RRPs
could be amplified up to 1 × 106.7 TCID50 in BHK cells or
293 cells infected with RRPs with the co-transfection of plas-
mids encoding Gn, Gc, and/or NSm. GFP-positive cells were
increased after serial passages or clonal selection using Geneticin.
The resulting replicon cell line did not contain detectable fowlpox
DNA, while S- and L-segment RNA encoded a few mutations.
Furthermore, the passage of replicon cells in the presence of
neutralizing serum did not result in a decrease in the num-
ber of GFP-positive cells. Mice were vaccinated once or twice
(i.m. or s.c.) with 1 × 106 TCID50 of RRPs and challenged with
M35/74 at day 42. The survival rate was 60, 60, 100 or 100% by
s.c. (x1), s.c. (x2), i.m. (x1) or i.m. (x2), respectively (Table 1).
Sheep were vaccinated once (i.m.) with 1 × 107 TCID50 of RRP
(non-spreading RVFV: NSR) and challenged with M35/74 at
day 19 post vaccination (Kortekaas et al., 2012). All vaccinated
sheep developed neutralizing antibodies, andwere protected from
viremia or illness after wt RVFV challenge (Table 1). Dodd et al.
generated ZH501 replicons by a different approach in which
BSR-T7/5 cells, which stably express T7 RNA polymerase, were
transfected with plasmids encoding genome S (NSs is replaced
with GFP) and L as well as plasmid encoding the ORF of Gn
and Gc (Dodd et al., 2012). Virus replicon particles (VRPRVF)
were directly collected from the supernatants with 100% effi-
ciency with titers ranging from 1 × 106 to 5 × 107 TCID50/ml.
All newborn suckling mice (2-day-old) inoculated (i.c.) with
1 × 104 or 1 × 105 TCID50 of VRPRVF survived. Mice vacci-
nated once (s.c.) with VRPRVF and challenged with ZH501 also
survived (Table 1). Furthermore, 80% protection was achieved
with 1 × 104 or 1 × 105 of VRPRVF by 2 days post-vaccination.
Those RVFV replicons are highly safe and immunogenic, and
will be suitable for use in both humans and animals. Further
improvements in process development will be required to scale-
up the production in certified cell substrates for industrial
manufacture.
ALPHAVIRUS REPLICONS
Alphaviruses (family Togaviridae), a member of positive-stranded
RNA viruses, have been used as replicons by expressing for-
eign gene in place of viral structural genes. Since structural
proteins are not expressed in replicon particles, antivector
responses are generally minimal (Rayner et al., 2002). Several
alphavirus replicons expressing RVFV NSm, Gn and/or Gc using
Sindbis (SIN) replicons and Venezuelan equine encephalitis virus
(VEEV) replicon (VEErep/Gn) were characterized (Gorchakov
et al., 2007). SIN replicons did not induce protection in mice,
whereas all mice vaccinated once (s.c.) with 1 × 106 pfu of
VEErep/Gn and challenged with ZH501 survived (Table 1) even
with neutralizing antibody titer below 1:80 before challenge.
However, the VEEVrep/Gn could not be passaged in cell cul-
ture due to strong interference of Gn with VEE replication. It
could be due to resistance to type-I IFN in cells supporting
VEEV replication. Two types of SIN replicons; REP91-RVF(M)
and Rgrid-RVF(M) were generated from AR86 and Girdwood
isolates from South Africa, respectively (Heise et al., 2009).
Mice vaccinated twice (footpad) with 1 × 105 IU of REP91-
RVF(M) or Rgrid-RVF(M) and challenged with wt RVFV all
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survived without overt signs of illness (Table 1). Prime-boost
vaccination using alphavirus replicon was tested in a mouse
model (Bhardwaj et al., 2010). Mice were vaccinated twice
(gene gun at 0 and 3 weeks) with 2μg of DNA encoding
RVFV Gn ectodomain (aa.131–557) fused to tandem repeats
of mouse homolog of C3d, and with VEE encoding the same
Gn ectodomain at 1 × 105 IU (footpad at 6 weeks). All mice
survived from ZH501 challenge, and induced mixed Th1/Th2
response, while mice vaccinated with DNA only (Gn-C3d) at 0,
3, and 6 weeks also survived from lethal challenge but induced
Th2-restricted immune response. Thus, alphavirus-based vac-
cine will be applicable to RVF vaccines for both human and
veterinary uses.
ADENOVIRUS REPLICONS
Adenovirus replicons are widely used for vaccine or gene ther-
apy, and accommodate large size (up to 37 kb) of foreign DNA
(Goncalves and de Vries, 2006). A complex adenovirus (CAdVax)
vector system is based on a modified Ad5sub360 vector back-
bone with deletions in E1, E3, and almost all E4 ORFs with the
exception of ORF6 (Wang et al., 2006). Holman et al. devel-
oped CAdVax encoding RVFV Gn and Gc (codon optimized
for humans) of MP-12 strain with human CD4 signal peptides
under human cytomegalovirus (CMV) promoter, designated as
CAdVax-RVF (Wang et al., 2006; Holman et al., 2009) for human
RVF vaccine. All CD1 mice vaccinated once or twice (i.p.) with
1 × 108 pfu of CAdVax-RVF and challenged with ZH501 strain at
11 or 27 weeks, respectively, survived (Table 1) (Holman et al.,
2009). To test the influence of pre-existing immunity against
adenovirus replicon, mice were immunized with 1 × 109 pfu
of CAdVax-D encoding dengue virus glycoprotein, and subse-
quently vaccinated with 1 × 106 (low dose) or 1 × 108 pfu (high
dose) of CAdVax-RVF 10 weeks later. Although the antibody
level was limited in low dose group, the high dose group showed
high levels of anti-Gn/Gc antibody responses. On the other hand,
only 25% of mice with a low dose survived challenge infection
compared to 75% survival in mice with a high vaccine dose, sug-
gesting the preexisting immunity could be overcome by increased
vaccine dose.
POXVIRUS VECTORS
Viral vectors work as platform technologies for several impor-
tant pathogens, and their development is important for
Biodefense vaccines inducing protective immunity against mul-
tiple pathogens with limited investment. Most types of vector
vaccines are very safe due to their highly attenuated backbone.
Poxvirus vector is heat-stable and suitable for long-term storage
of vaccine, and allows stable insertion of one or more foreign
genes (Henderson and Moss, 1999). The WR strain of vac-
cinia virus (genus orthopoxvirus) is neurovirulent (Buller et al.,
1985). It was modified to express RVFV Gn and Gc in place
of thymidine kinase (TK), and found to be highly attenuated
(Collett et al., 1987). Papin et al. used attenuated recombinant
Copenhagen strain (vCO) which lacks IFN-γ receptor homolog
gene (B8R) and encodes TK gene inactivated by the expression
of RVFV Gn and Gc (vCOGnGc) or Gn, Gc and human IFN-γ
(vCOGnGcγ) in place of TK (Papin et al., 2011). Severe combined
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immunodeficiency (SCID) mice vaccinated (i.p.) with 1 × 107
pfu of either vaccines did not manifest weight loss nor death,
suggesting their safety. CB6F1 mice immunized (i.m.) twice with
vCOGnGc or vCOGnGcγ were challenged with ZH501 strain
resulting in 90 or 60% protection, respectively, while single dose
vaccination conferred only 50 or 10% protection, respectively
(Table 1). Papio cynocephalus anubis baboons vaccinated with
vCOGnGc by scarification at day 0 (1 × 107 pfu), and i.m. booster
at day 28 (1 × 109 pfu) induced PRNT80 1:512 or more, while
vaccination with a single dose induced PRNT80 1:16 to 1:64 by
day 28. Thus, vCOGnGc will be a safe and heat-stable candidate
RVF vaccine for humans.
An attenuated Lumpy skin disease virus (LSDV) KS1 strain of
Capripoxvirus (CPV) (genus capripoxvirus), derived from a viru-
lent field isolate (LSDV 0240 strain), was modified as a vector for
RVFV Gn and Gc (rLSDV-RVFV or rKS1/RVFV) (Wallace et al.,
2006; Soi et al., 2010). LSD is endemic to Africa, while the vec-
tor has restricted host range to ruminants, and confers potential
cross-protection from sheep pox or goat pox in ruminants. Sheep
vaccinated twice with 1 × 106 or 1 × 107 pfu of rLSDV-RVFV
(i.d.) did not show an increase in rectal temperature after chal-
lenge with wt RVFV or sheep poxvirus (Table 1) (Wallace et al.,
2006). On the other hand, sheep vaccinated twice with other sim-
ilar CPV vector vaccine, rKS1/RVFV (s.c.), and challenged with
wt RVFV did not induce viremia, while those inoculated with
saline or rKS lacking RVFV Gn/Gc induced 101–104 TCID50/ml
of viremia (Soi et al., 2010). Also, sera derived from those sheep
vaccinated with rKS1/RVFV neutralized both RVFV and sheep
poxvirus, and no vaccinated sheep developed fever or skin lesions
after sheep poxvirus challenge. Effect of preexisting antibodies
against sheep poxvirus was also evaluated (Soi et al., 2010). Sheep
challenged with sheep poxvirus 1 month before vaccination with
rKS1/RVFV raised detectable neutralizing antibodies only after
booster, while all vaccinated sheep did not show viremia after
RVFV challenge. Those LSDV vaccines could also confer protec-
tive immunity in mice regardless of host range of CPV (Wallace
et al., 2006; Soi et al., 2010; Ayari-Fakhfakh et al., 2012). Although
LSDV is classified as a select agent by USDA, the vaccine will be
suitable for dual vaccination of ruminants for CPV diseases and
RVF in endemic countries.
NEWCASTLE DISEASE VIRUS VECTORS
Newcastle disease virus (NDV) (genus Avulavirus, family
Paramyxoviridae) causes diseases in all birds, and three patho-
types are known; lentogenic (no disease), mesogenic (interme-
diate), and velogenic (highly virulent) (Huang et al., 2003). The
non-segmented negative-stranded RNA (15,186 nt.) genome has
six structural genes; 5′-NP-P-M-F-HN-L-5′. Lentogenic LaSota
strain has been used as a live-attenuated vaccine for NDV in
poultry, and the recombinant LaSota strain encoding foreign
genes was developed for vaccine use by using reverse genetics
(Peeters et al., 1999; Romer-Oberdorfer et al., 1999; Huang et al.,
2001). The virus is non-pathogenic to mammals, the V pro-
tein encodes host-specific IFN antagonist activity (Park et al.,
2003), and there is less chance of any pre-existing immunity
to the virus because mammals are not the natural hosts of
NDV. In addition, NDV-based vaccine can be produced in
embryonated eggs, a technology that is already available for
influenza vaccine production and easily scalable for industrial
production.
NDV-based vaccine is considered as a veterinary vaccine can-
didate for RVF. Recombinant NDV LaSota strain expressing
RVFV Gn in place of NDV M (matrix protein) (NDFL-Gn) was
generated and characterized (Kortekaas et al., 2010a). Cattle vac-
cinated twice with NDVFL-Gn vaccine developed 1:8–1:32 of
neutralizing antibodies (Cytopathic Effect Neutralization Test,
CPENT: endpoint of serum dilution with 100% inhibition of
cytopathic effect) (Swanepoel et al., 1986) by i.m. route but
not by i.n. route. NDFL2-GnGc which encodes both Gn and
Gc was also generated, and produced virus-like particles con-
sisting of Gn and Gc in allantoic fluid in embryonated eggs
(sucrose density 1.14–1.15 g/cm3) distinct from that of paramyx-
ovirus (1.18–1.20 g/cm3), while it remains unknown whether
the NDFL2-GnGc incorporated Gn and Gc into NDV virions
(Kortekaas et al., 2010b). All the Balb/c mice vaccinated twice
(i.m.) with 1 × 105.3 TCID50 of NDFL2-GnGc and challenged
with wt RVFV strain survived (Table 1) without the increase in
anti-N antibody suggesting the vaccination induced sterile immu-
nity. Lambs vaccinated twice (i.m.) with 1 × 107.3 TCID50 of
NDFL2-GnGc developed more than 1:100 of neutralizing anti-
body (CPENT) (Kortekaas et al., 2012). Similar neutralizing
response induced by i.m. route was obtained by s.c., while i.n.
administration did not elicit neutralizing antibody responses in
sheep (Harmsen et al., 2011). In the subsequent study, lambs
vaccinated once (i.m.) with 1 × 107 TCID50 of NDFL2-GnGc
(NDV-GnGc) and challenged with wt RVFV at day 19 post-
vaccination showed reduced viremia without significant change
in rectal temperature (Table 1), whereas neutralizing antibody
was developed only in 33% before challenge (Kortekaas et al.,
2012).
CONCLUDING REMARKS
Next generation vaccines are probably superior to traditional
vaccines in safety or immunogenicity. However, the informa-
tion of safety and immunogenicity is still limited to specific
animal models. It is unclear how the variety of assay proce-
dures (e.g., route, dose, virus/host strains, antibody detection
method, etc.) by different laboratories affects the interpretation
of their efficacy results. Most vaccine candidates will further
require rigorous safety and efficacy testing using appropriate
animal models before human clinical trials. The correlation of
neutralizing antibody level with prevention of viremia and clin-
ical signs should be analyzed in mouse models, ruminants,
and non-human primates for those novel vaccine candidates in
the future.
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